OakChart

Biogen Inc

BIIBHealthcare·Drug Manufacturers - General·USA·Large·NASD·Nov 11 • 11:38 AM ET

251.78-1.47 (-0.58%)
2026-11-11 17:38 CET
Market cap
37,435.42 USD m
Revenue, TTM
9,897.90 USD m
Net income, TTM
347.50 USD m
Free cash flow, TTM
2,070.70 USD m
EPS diluted, TTM
2.34
P/E
107.79
Compare

Price

BIIB against its 20, 50 and 200-day averages
2050200miss
175.00200.00225.00250.001.9M3.9MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BIIBclose 251.7820-day 247.3550-day 232.18200-day 204.38251.7852w high

3.5% under the 52-week high of 261.00 on 9 Nov 2026. 52-week low 154.20 on 11 Nov 2025. Last 15 sessions, 8.8% high to low

Profile

BIIB
52-week range, 91% of the way up
154.2261

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

IndexS&P 500, RUI
Employees7500
IPOSep 17, 1991
Beta0.09
ATR, 14d8.04
Rel volume0.36
Short float3.72%
Insider own0.75%
Inst own98.99%

Snapshot

6 groups

Valuation

IndexS&P 500, RUI
Market Cap37.22B
Enterprise Value43.72B
Income347.50M
Sales9.90B
Book/sh128.03
Cash/sh8.82
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees7500
IPOSep 17, 1991

Ratios

P/E107.79
Forward P/E15.51
PEG2.46
P/S3.76
P/B1.97
P/C28.54
P/FCF17.97
EV/EBITDA16.84
EV/Sales4.42
Quick Ratio1.37
Current Ratio1.95
Debt/Eq0.41
LT Debt/Eq0.39
Option/ShortYes / Yes

Earnings

EPS (ttm)2.34
EPS next Y16.23
EPS next Q2.81
EPS this Y-18.17%
EPS next Y29.84%
EPS next 5Y6.31%
EPS past 3/5Y-25.04% -18.74%
Sales past 3/5Y0.35% -5.06%
EPS Y/Y TTM-78.55%
Sales Y/Y TTM2.15%
EPS Q/Q-104.40%
Sales Q/Q9.63%
EarningsOct 28 BMO
EPS/Sales Surpr.31.53% 6.43%

Ownership

Insider Own0.75%
Insider Trans-0.11%
Inst Own98.99%
Inst Trans3.39%
ROA1.13%
ROE1.87%
ROIC1.32%
Gross Margin64.00%
Oper. Margin17.31%
Profit Margin3.51%
SMA201.79%
SMA508.44%
SMA20023.19%
Trades-

Technical

Shs Outstand147.80M
Shs Float146.71M
Short Float3.72%
Short Ratio5.14
Short Interest5.45M
52W High261.00 -3.53%
52W Low154.20 63.28%
Volatility4.07% 3.24%
ATR (14)8.04
RSI (14)58.26
Beta0.09
Rel Volume0.36
Avg Volume1.06M
Volume140,040

Performance

Perf Week-1.05%
Perf Month9.99%
Perf Quarter19.52%
Perf Half Y23.10%
Perf YTD43.06%
Perf Year57.80%
Perf 3Y12.01%
Perf 5Y-5.55%
Perf 10Y-14.36%
Recom1.74
Target Price270.66
Prev Close253.25
Price251.78
Change %-0.58%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 29, 2026UpgradeAArgusHold → Buy$280+11.2%
Oct 12, 2026UpgradeJJP MorganNeutral → Overweight$300+19.2%
Aug 13, 2026UpgradeWWolfe ResearchPeer Perform → Outperform$300+19.2%
Jul 13, 2026UpgradeTTruistHold → Buy$235-6.7%
Jun 08, 2026UpgradeNNeedhamHold → Buy$255+1.3%
May 15, 2026ResumedEEvercore ISIOutperform
Apr 22, 2026UpgradeUUBSNeutral → Buy$225-10.6%
Apr 20, 2026UpgradeWWells FargoEqual Weight → Overweight$250-0.7%
Apr 14, 2026UpgradePPiper SandlerNeutral → Overweight$214-15.0%
Feb 20, 2026InitiatedBBarclaysEqual Weight$185-26.5%

Peers

Mkt cap
TickerCompanyMkt cap
NVSNovartis AG ADR291.86B
LLYLilly(Eli) & Co1337.82B
SNYSanofi ADR114.38B
AMGNAMGEN Inc249.64B
IONSIonis Pharmaceuticals Inc4.81B
GILDGilead Sciences Inc209.96B
ARGXArgen X SE ADR61.03B
REGNRegeneron Pharmaceuticals Inc94.68B
SRPTSarepta Therapeutics Inc1.77B
SUPNSupernus Inc6.09B

Insider trading

latest 14 of 26
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Grogan JaneHead of ResearchOct 30 '26Option Exercise0.0069504,753Nov 02 05:37 PM
Godbout SeanChief Accounting OfficerOct 02 '26Option Exercise0.002701,467Oct 05 05:00 PM
Minor LloydDirectorAug 03 '26Sale203.34593120,5813,282Aug 05 04:03 PM
Minor LloydDirectorAug 04 '26Sale200.96593119,1692,689Aug 05 04:03 PM
Minor LloydDirectorAug 04 '26Proposed Sale200.96593119,169Aug 04 11:22 AM
Minor LloydDirectorAug 03 '26Proposed Sale203.34593120,581Aug 03 01:02 PM
Pangalos Menelas NDirectorJun 09 '26Option Exercise0.002,37002,370Jun 11 05:21 PM
Keeney AdamHead of Corporate DevelopmentMay 01 '26Option Exercise0.0093906,820May 05 04:11 PM
Godbout SeanChief Accounting OfficerApr 01 '26Option Exercise0.0018101,396Apr 03 04:05 PM
Murphy NicoleHead of Pharm Ops and TechFeb 12 '26Buy195.03358519,611Feb 17 08:16 PM
Viehbacher ChristopherPresident and CEOFeb 06 '26Option Exercise0.0024,461036,548Feb 10 05:06 PM
Singhal PriyaHead of DevelopmentFeb 06 '26Option Exercise0.006,900012,115Feb 10 05:05 PM
Singhal PriyaHead of DevelopmentFeb 09 '26Sale199.832,660531,5488,043Feb 10 05:05 PM
Murphy NicoleHead of Pharm Ops and TechFeb 06 '26Option Exercise0.008,725021,016Feb 10 05:03 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VOOVanguard S&P 500 ETFAUM: 1054.75B
VOVanguard Morningstar Mid-Cap ETFAUM: 107.07B
IVViShares Core S&P 500 ETFAUM: 871.38B
SPYSPDR S&P 500 ETF TrustAUM: 793.23B
VTVVanguard Morningstar Value ETFAUM: 196.23B
IBBiShares Biotechnology ETFAUM: 11.36B
XLVState Street Health Care Select Sector SPDR ETFAUM: 50.35B
RSPInvesco S&P 500 Equal Weight ETFAUM: 104.94B
VOEVanguard Morningstar Mid-Cap Value ETFAUM: 24.66B

News

latest 14 of 206
  • ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure (GlobeNewswire)
  • While biotech bets swing on trial data, this dividend payer gained 72% since 2024 (Investing.com)
  • Stoke Therapeutics to Present at Upcoming Investor Conferences in November (Business Wire)
  • Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates (Business Wire)
  • Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026 (GlobeNewswire)
  • Loading…
  • Biogen Q3 Earnings Beat Estimates as Revenue Rises 11% and 2026 Profit Guidance Improves (InvestorsHub)
  • Big Day for Econ Data, Hyperscaler Earnings (Zacks)
  • Biogen Swings to Loss, Logs Higher Sales (The Wall Street Journal)
  • Biogen beats Q3 estimates, raises guidance floor on growth (Investing.com)
  • Biogen Has 'Returned To Growth,' Says CEO - What To Know About Its Report (Investor's Business Daily)
  • Biogen Crushes Earnings Estimates. As Old Blockbusters Fade, New Bets Pick Up the Slack. (Barrons.com)
  • Corxel, an obesity drugmaker, to go public via SPAC deal (BioPharma Dive)
  • The Week Ahead: Wall Street Awaits October Fed Decision (Schaeffer's Research) +5.34%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-282.6201.992-0.1402,8042,63527
2026Q22026-07-293.6002.9390.6562,7362,46027
2026Q12026-04-293.5703.0542.1532,4782,28729
2025Q42026-02-061.9901.625-0.3332,2792,20327
2025Q32025-10-304.8103.8823.1712,5352,34027
2025Q22025-07-315.4703.8994.3272,6462,32828
2025Q12025-05-013.0202.8991.6412,4312,23426
2024Q42025-02-123.4403.3311.8262,4552,40825
2024Q32024-10-304.0803.7722.6592,4662,43527
2024Q22024-08-015.2804.0684.0002,4652,39228
2024Q12024-04-243.6703.4702.6962,2912,30928
2023Q42024-02-132.9503.1841.7142,3862,46628
2023Q32023-11-084.3603.974-0.4702,5302,40025
2023Q22023-07-254.0203.7774.0662,4562,36726
2023Q12023-04-253.4003.2782.6722,4632,34224
2022Q42023-02-154.0503.4893.7912,5442,44526

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY33.57033.24331.42214,37814,244
2020FY33.70033.79024.80213,44513,380
2021FY19.22019.19210.40210,98210,872
2022FY17.67017.10820.86910,17310,073
2023FY14.72014.9957.9759,8369,928
2024FY16.47016.37811.1879,6769,636
2025FY15.28014.9408.7909,8919,826
2026FY-12.504--10,598
2027FY-16.235--10,802
2028FY-18.358--11,137
2029FY-20.123--11,428
2030FY-20.382--11,589

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-06244112,6072,4703,378
2026Q4S2026-10-30254112,6062,4703,378
2026Q4S2026-10-29253112,5762,4702,674
2026Q4S2026-10-28253102,5772,4702,674
2026Q4S2026-10-2725532,6092,4912,686
2026Q4S2026-10-2225532,6092,4912,686
2026Q4S2026-10-1625522,6112,4912,686
2026Q4S2026-10-1425422,6072,4912,686
2026Q4S2026-10-1225512,6102,5082,686
2026Q4S2026-10-09251842,6112,5082,713
2026Q4S2026-10-08251842,6102,5082,713
2026Q4S2026-10-07251842,6072,5082,713
2026Q4S2026-10-02251842,6052,5082,713
2026Q4S2026-09-01251842,6032,5082,713

Estimate history

EPS, annual11.9221.5831.42224.80210.40220.8697.97511.1878.7892.3359
Period201720182019202020212022202320242025TTM
EPS, quarterly2.6591.8261.6414.3273.171-0.3332.1530.656-0.139
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual1099012052.7127141235610402.49433.494179266.69533.19897.9
Period201720182019202020212022202320242025TTM
Sales, quarterly2375.72337.623362561.52454.82180.82403.32622.52691.3
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual211.5197.2174.2152.4147144.1144.9145.8146.8147.8
Period201720182019202020212022202320242025MRQ
Shares, quarterly145.7145.8146.5146.6146.7146.8147.6147.7147.8
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue9,897.909,533.109,266.609,417.009,433.4010,402.4012,356.0012,714.0012,052.70
Cost of Goods Sold Incl. D&A3,563.103,079.202,983.603,028.202,797.002,597.002,262.202,420.002,197.50
Gross Profit6,334.806,453.906,283.006,388.806,636.407,805.4010,093.8010,294.009,855.20
Selling, General and Administrative Excl. Other4,621.003,909.604,158.804,757.504,362.304,940.206,293.504,464.704,692.60
Research and Development1,872.501,481.401,755.102,207.801,958.702,265.903,789.002,090.002,597.20
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income1,713.802,544.302,124.201,631.302,274.102,865.203,800.305,829.305,162.60
Interest Expense304.90267.50250.30246.90246.60253.60225.80187.40200.60
Unusual Expense1,135.40845.8069.20217.401,006.50648.30175.30143.80476.40
Net Income Before Taxes445.101,556.501,906.001,296.803,591.801,745.205,047.507,125.905,899.60
Income Taxes97.60263.60273.80135.30632.8052.50992.301,158.001,425.60
Consolidated Net Income347.501,292.901,632.201,161.502,961.601,727.604,060.505,888.504,474.00
Net Income From Continuing Operations347.501,292.901,632.201,161.103,046.901,556.104,000.605,888.504,430.70
Net Income347.501,292.901,632.201,161.103,046.901,556.104,000.605,888.504,430.70
EPS (Recurring)7.7312.8111.529.0225.6913.4425.5631.9623.21
EPS (Basic, Before Extraordinaries)2.368.8311.218.0220.9710.4424.8631.4721.62
EPS (Diluted)2.348.7911.197.9720.8710.4024.8031.4221.58
EBITDA2,595.603,324.202,797.402,126.102,792.803,352.504,257.306,293.905,813.20
Non-Operating Income (Expense)171.60125.50101.30129.802,570.80-218.101,648.301,627.801,414.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense243.10234.10279.00216.78263.50246.60171.60180.80142.60
Price To Earnings Ratio108.42108.4213.8125.7314.1123.0810.019.4313.93
Price To Sales Ratio3.372.722.414.004.293.453.204.375.13
Gross Margin64.0067.7067.8067.8470.3575.0381.6980.9781.77
Operating Margin17.3126.6922.9217.3224.1127.5430.7645.8542.83
Net Margin3.5113.5617.6112.3332.3014.9632.3846.3236.76
Shares Outstanding147.80146.80145.80144.90144.10147.00152.40174.20197.20
Market Capitalization37,435.4237,435.4222,283.3537,495.2639,876.7635,242.5737,679.5553,542.5560,630.26

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue2,691.302,622.502,403.302,180.802,454.802,561.502,336.002,337.60
Cost of Goods Sold Incl. D&A989.501,013.00865.40695.20876.60799.30812.50807.50
Gross Profit1,701.801,609.501,537.901,485.601,578.201,762.201,523.501,530.10
Selling, General and Administrative Excl. Other1,257.701,171.401,078.401,113.50964.40915.90935.201,139.50
Research and Development505.70461.70471.10434.00369.60332.10362.70459.50
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income444.10438.10459.50372.10613.80846.30588.30390.60
Interest Expense87.5082.3067.6067.5067.4072.6060.0060.00
Unusual Expense406.20345.7081.80301.707.6035.70252.90-2.30
Net Income Before Taxes-9.00132.40377.70-56.00557.30744.00311.20291.50
Income Taxes11.6034.9058.20-7.1090.80109.2070.7024.70
Consolidated Net Income-20.6097.50319.50-48.90466.50634.80240.50266.80
Net Income From Continuing Operations-20.6097.50319.50-48.90466.50634.80240.50266.80
Net Income-20.6097.50319.50-48.90466.50634.80240.50266.80
EPS (Recurring)1.782.282.541.113.214.502.851.82
EPS (Basic, Before Extraordinaries)-0.140.662.17-0.333.184.331.651.83
EPS (Diluted)-0.140.662.15-0.333.174.331.641.83
EBITDA685.20674.20663.90572.30816.001,040.60771.50614.60
Non-Operating Income (Expense)40.60122.3067.60-58.9018.506.0035.80-72.20
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense65.3062.1067.5048.2060.9060.0065.00107.65
Price To Earnings Ratio108.4223.1920.8216.0513.4012.4012.2413.81
Price To Sales Ratio3.373.332.832.712.131.922.132.41
Gross Margin63.2361.3763.9968.1264.2968.8065.2265.46
Operating Margin16.5016.7119.1217.0625.0033.0425.1816.71
Net Margin-0.773.7213.29-2.2419.0024.7810.3011.41
Shares Outstanding147.80147.70147.60146.80146.70146.60146.50145.80
Market Capitalization37,435.4231,898.4526,905.3325,818.0820,537.8318,402.4520,029.9622,283.35

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments3,815.702,375.001,049.904,892.803,802.502,610.104,475.903,538.003,689.00
Short Term Receivables1,867.001,868.802,100.002,136.401,961.702,327.302,470.702,485.402,319.60
Inventories2,168.102,460.502,527.401,344.401,351.501,068.60804.20929.90902.70
Other Current Assets1,123.30752.501,182.001,417.60740.80881.10631.00687.60962.00
Total Current Assets8,974.107,456.806,859.309,791.207,856.506,887.108,381.807,640.907,873.30
Net Property, Plant & Equipment3,320.803,537.703,729.703,702.503,791.803,844.803,674.303,601.203,182.40
Total Investments and Advances618.90226.70460.701,957.102,602.203,416.902,382.202,732.803,143.10
Intangible Assets15,669.6016,170.1014,582.207,599.107,982.408,846.409,285.208,826.408,512.10
Deferred Tax Assets292.50324.20928.601,226.401,415.101,369.503,232.102,153.90595.90
Other Assets563.60333.80284.30277.80229.30254.20278.70333.70345.80
Total Assets29,439.5028,049.3026,844.8024,554.1023,877.3024,618.9027,234.3025,288.9023,652.60
Short Term Debt Incl. Current Port. of LT Debt80.401,835.00240.3097.201,088.2083.201,569.400.003.20
Accounts Payable432.00424.20403.30491.50589.20454.90530.80370.50395.50
Income Tax Payable114.80548.30257.40259.90174.70142.0071.4063.5068.20
Other Current Liabilities2,722.202,721.302,533.302,424.202,446.103,062.102,692.202,861.202,901.30
Total Current Liabilities3,349.405,528.803,434.303,272.804,298.203,742.204,863.803,295.203,368.20
Long Term Debt6,577.204,881.707,188.206,614.006,604.407,828.204,871.705,936.505,935.00
Provision for Risks Charges0.000.000.000.000.000.000.00409.80523.60
Deferred Tax Liabilities507.60190.50641.80334.70694.501,032.802,810.801,636.20122.60
Other Liabilities748.50732.30781.10944.201,320.501,329.601,348.90979.601,105.10
Total Liabilities11,182.7011,333.3012,045.4011,165.7012,917.6013,932.8013,895.2012,257.3011,054.50
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity18,256.8016,716.0014,799.4013,397.9010,896.2010,700.3013,343.2013,039.6012,612.80
Total Shareholders Equity18,256.8016,716.0014,799.4013,397.9010,896.2010,700.3013,343.2013,039.6012,612.80
Accumulated Minority Interest0.000.000.00-9.5063.50-14.20-4.10-8.00-14.70
Total Equity18,256.8016,716.0014,799.4013,388.4010,959.7010,686.1013,339.1013,031.6012,598.10
Total Liabilities & Stockholders Equity29,439.5028,049.3026,844.8024,554.1023,877.3024,618.9027,234.3025,288.9023,652.60
Book Value Per Share124.37114.65102.1492.9874.1270.2176.6066.1259.63
Tangible Book Value Per Share17.623.741.5040.2419.8212.1623.3021.3719.39
Full-Time Employees7,5007,6057,5708,7259,6109,1007,4007,8007,300
Price to Book Ratio1.981.362.593.123.243.493.874.555.24
Return on Assets4.505.954.5212.586.4215.4322.4218.1110.91
Return on Equity7.3910.368.2425.0814.4133.2844.6434.5420.52
Return on Invested Capital5.217.565.2815.238.8921.5932.3323.3513.69
Quick Ratio2.030.901.262.581.511.551.562.042.07
Current Ratio2.681.352.002.991.831.841.722.322.34

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income347.501,292.901,632.201,161.502,961.601,727.604,060.505,888.504,474.00
Depreciation881.80779.90673.20494.80518.40487.70457.20464.60650.60
Other Funds (Non Cash)1,496.30827.80883.40845.40-1,036.801,996.90-249.70459.00554.60
Funds from Operations3,012.003,262.203,030.702,195.902,274.603,785.404,417.006,879.305,787.50
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-764.90-1,057.60-155.20-648.70-890.30-145.50-187.20199.30400.20
Cash from Operating Activities2,247.102,204.602,875.501,547.201,384.303,639.904,229.807,078.606,187.70
Capital Expenditures-602.70-235.40-359.80-311.40-243.20-294.90-551.80-669.50-886.10
Net Assets From Acquisitions-5,071.100.00-1,074.80-6,926.100.000.000.00-744.40-
Sale of Fixed Assets and Businesses0.000.000.0012.30595.0028.100.00923.70-
Purchase or Sale of Investments155.10-1,178.60551.503,147.801,212.80-309.80-29.901,233.70339.40
Purchase of Investments-2,063.90-1,258.300.00-5,140.70-3,448.50-3,808.70-7,404.20-5,252.60-8,834.30
Sale Or Maturity of Investments2,219.0079.70551.508,288.504,661.303,498.907,374.306,486.309,173.70
Other Uses-6.500.00-4.70-11.300.000.00-26.90-300.00-1,500.00
Other Sources-42.9088.600.0024.4012.900.0027.000.40
Cash from Investing Activities-5,502.50-1,371.10-799.20-4,088.701,589.00-563.70-608.60470.50-2,046.30
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock-42.90-10.00-31.30-44.30-751.90-1,800.70-6,683.70-5,868.30-4,352.60
Repurchase of Common Pref Stock0.000.000.000.00-750.00-1,800.00-6,679.10-5,868.30-4,352.60
Sale of Common Pref Stock-42.90-10.00-31.30-44.30-1.90-0.70-4.600.000.00
Proceedsfrom Stock Options-42.90-10.00-31.30-44.30-1.90-0.70-4.600.000.00
Issuance or Reduction of Debt, Net903.30-16.90-650.00187.30-1,002.20-170.001,467.400.00-3.20
Change in Long Term Debt903.30-16.90-650.00187.30-1,002.20-170.001,467.400.00-3.20
Issuance of Long Term Debt2,400.001,733.100.00997.200.000.002,967.400.000.00
Reduction of Long Term Debt-1,496.70-1,750.00-650.00-809.90-1,002.20-170.00-1,500.000.00-3.20
Net Financing Active Other Cash Flow-139.00-275.00-2.20-6.00-5.60-115.50-56.407.90-116.20
Other Financing Activities Uses-138.70-280.00-2.20-6.00-5.60-115.50-71.000.00-116.20
Cash from Financing Activities721.40-301.90-683.50137.00-1,759.70-2,086.20-5,272.70-5,860.40-4,472.00
Exchange Rate Effect-24.90101.90-67.7035.10-55.70-59.8069.000.40-18.60
Net Change in Cash-2,558.90633.501,325.10-2,369.401,157.90930.20-1,582.501,689.10-349.20
Free Cash Flow2,070.702,050.802,721.801,270.201,144.003,381.803,805.006,564.105,417.10
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow16.1212.628.2029.6635.3410.6110.388.4711.40
Deferred Taxes & Investment Tax Credit-361.60-158.10-305.80-168.60-426.80149.0067.10108.30

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments1,303.901,285.004,282.703,815.703,960.402,758.80
Short Term Receivables2,382.602,398.401,790.401,867.001,850.002,084.00
Inventories2,224.402,384.301,949.002,168.102,209.402,274.30
Other Current Assets1,673.501,238.001,168.301,123.30916.80850.60
Total Current Assets7,584.407,305.709,190.408,974.108,936.607,967.70
Net Property, Plant & Equipment3,143.703,239.803,269.203,320.803,406.203,433.30
Total Investments and Advances172.50256.40676.80618.90167.10224.00
Intangible Assets20,372.5020,507.2015,542.2015,669.6015,822.6015,960.60
Deferred Tax Assets293.70202.10238.20292.50312.40330.90
Other Assets487.30575.40566.30563.60562.60413.70
Total Assets32,054.1032,086.6029,483.1029,439.5029,207.5028,330.20
Short Term Debt Incl. Current Port. of LT Debt400.00800.000.0080.400.000.00
Accounts Payable430.30403.90358.50432.00413.10408.40
Income Tax Payable54.5086.9093.60114.80103.30114.80
Other Current Liabilities3,013.602,626.302,546.802,722.202,773.602,660.50
Total Current Liabilities3,898.403,917.102,998.903,349.403,290.003,183.70
Long Term Debt7,401.307,555.106,561.906,577.206,590.106,594.60
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities1,163.90945.50483.50507.60358.10118.30
Other Liabilities668.40820.90787.10748.50761.80799.60
Total Liabilities13,132.0013,238.6010,831.4011,182.7011,000.0010,696.20
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity18,922.1018,848.0018,651.7018,256.8018,207.5017,634.00
Total Shareholders Equity18,922.1018,848.0018,651.7018,256.8018,207.5017,634.00
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity18,922.1018,848.0018,651.7018,256.8018,207.5017,634.00
Total Liabilities & Stockholders Equity32,054.1032,086.6029,483.1029,439.5029,207.5028,330.20
Book Value Per Share128.03127.61126.37124.37124.11120.29
Tangible Book Value Per Share-9.81-11.2321.0717.6216.2611.41
Full-Time Employees---7,500--
Price to Book Ratio1.981.711.471.421.161.08
Return on Assets1.132.764.774.505.595.55
Return on Equity1.874.587.707.399.319.13
Return on Invested Capital-0.080.371.27-0.201.882.62
Quick Ratio1.371.262.412.032.041.79
Current Ratio1.951.873.062.682.722.50

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-20.6097.50319.50-48.90466.50634.80
Depreciation241.10236.10204.40200.20202.20194.30
Other Funds (Non Cash)587.00381.00225.90302.40175.80152.70
Funds from Operations931.00687.00773.40620.601,098.30950.50
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-290.20-238.10-127.90-108.70174.20-789.60
Cash from Operating Activities640.80448.90645.50511.901,272.50160.90
Capital Expenditures-265.40-140.90-86.20-110.20-51.50-26.60
Net Assets From Acquisitions-6.00-5,065.100.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments55.001,367.40-123.10-1,144.20-34.400.00
Purchase of Investments0.00-147.80-748.80-1,167.30-91.000.00
Sale Or Maturity of Investments55.001,515.20625.7023.1056.600.00
Other Uses-5.70-0.60-0.200.0030.60-30.40
Other Sources--0.0022.7020.20-
Cash from Investing Activities-222.10-3,839.20-209.50-1,231.70-35.10-57.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock3.206.00-55.103.005.206.10
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock3.206.00-55.103.005.206.10
Proceedsfrom Stock Options3.206.00-55.103.005.206.10
Issuance or Reduction of Debt, Net-400.001,303.300.000.00-0.30-16.60
Change in Long Term Debt-400.001,303.300.000.00-0.30-16.60
Issuance of Long Term Debt0.002,400.000.000.00-0.301,733.40
Reduction of Long Term Debt-400.00-1,096.700.000.000.00-1,750.00
Net Financing Active Other Cash Flow3.00-13.3011.30-140.00-135.10-1.20
Other Financing Activities Uses2.00-2.000.00-138.70-141.300.00
Cash from Financing Activities-393.801,296.00-43.80-137.00-130.20-11.70
Exchange Rate Effect-48.8039.40-18.002.50-3.2068.30
Net Change in Cash-23.90-2,054.90374.20-854.301,104.00160.50
Free Cash Flow600.40408.00594.30468.001,226.30134.30
Price to Free Cash Flow16.1211.9111.2312.598.949.31

Revenue breakdown

Alzheimer's Collaboration2024: 59.90M 2025: 177.70M
Contract Manufacturing, Royalty And Other2024: 652.60M 2025: 732.90M
Product2024: 7.21B 2025: 7.12B
Revenues from anti-cd20 therapeutic programs2024: 1.75B 2025: 1.86B
United States2024: 9.68B 2025: 9.89B
Consolidation, Policy2024: 59.90M
Reportable2024: 9.62B
Total Biological Products, (No Diagnostic Substances) revenue2025: 9.89B

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.72%5.5M146.7M1.04M
2026-10-153.75%5.5M146.6M1.01M
2026-09-304.07%6.0M146.6M1.08M
2026-09-153.97%5.8M146.6M1.10M
2026-08-313.91%5.7M146.6M1.12M
2026-08-143.54%5.2M146.6M1.20M
2026-07-313.72%5.5M146.4M1.24M
2026-07-154.10%6.0M146.3M1.26M
2026-06-303.91%5.7M146.3M1.23M
2026-06-153.55%5.2M146.3M1.16M
2026-05-293.26%4.8M146.3M1.15M
2026-05-153.23%4.7M146.3M1.14M
2026-04-303.05%4.5M146.6M1.26M
2026-04-153.03%4.4M145.7M1.27M
2026-03-312.61%3.8M146.4M1.32M
2026-03-132.96%4.3M146.4M1.63M
2026-02-272.87%4.2M146.4M1.76M
2026-02-133.10%4.5M146.4M1.96M
2026-01-303.20%4.7M146.4M1.96M
2026-01-153.19%4.7M146.4M1.99M

Option chain

expiry 2026-11-13
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call115134.9138.20.006.1530.000.000.983-1.1100.008
call120129.9133.20.005.8550.000.000.982-1.1030.008
call125124.9128.20.005.5690.000.000.981-1.0950.009
call130119.8123.40.004.8110.000.000.980-1.0850.009
call135114.8118.10.004.9540.000.000.979-1.0790.010
call140109.8113.40.004.9110.000.000.978-1.0700.010
call145104.8108.40.004.6590.000.000.976-1.0600.010
call15099.80103.40.004.4140.000.000.975-1.0500.011
call15594.8098.400.004.1770.000.000.974-1.0400.011
call16089.8093.100.003.7700.000.000.972-1.0280.012
call16584.9088.300.003.6680.000.000.970-1.0160.013
call17079.9083.500.003.5540.000.000.969-1.0030.013
call17574.8078.200.003.1900.000.000.967-0.9890.014
call18069.9073.200.002.9860.000.000.965-0.9750.015
call18564.8068.400.002.8770.000.000.962-0.9590.015
call19059.8063.300.002.6340.000.000.959-0.9420.016
call19554.8058.300.002.4390.000.000.956-0.9240.017
call20049.8053.400.002.2860.000.000.953-0.9040.018
call20544.8048.500.002.1310.000.000.949-0.8810.020
call21039.8043.500.001.6200.000.000.944-0.8560.021
call212.537.3041.000.001.8420.000.000.941-0.8440.022
call21534.9038.600.001.7770.000.000.938-0.8310.023
call217.532.4035.900.001.6220.000.000.935-0.8160.024
call22029.9033.600.001.5850.000.000.931-0.8000.025
call222.527.4031.100.001.4890.000.000.927-0.7830.026
call22525.1027.8027.901.1202.000.000.922-0.7650.027
call227.522.4025.900.001.2470.000.000.916-0.7530.029
call23020.0022.9026.470.9833.000.000.907-0.7610.031
call232.517.5020.900.001.0570.000.000.893-0.7780.035
call23515.0018.0018.400.86730.000.000.885-0.7340.036
call237.512.6016.0017.000.8831.000.000.842-0.9250.045
call24010.2013.4011.300.7623.001.000.825-0.8700.048
call242.58.0011.0011.750.6561.000.000.805-0.8110.052
call2455.909.009.580.68310.000.000.752-0.8460.059
call247.54.407.2010.500.6331.000.000.640-1.2390.070
call2503.105.104.990.55021.000.000.570-1.2100.074
call252.51.453.904.040.5623.000.000.486-1.1060.075
call2550.203.607.910.66612.000.000.413-1.2290.073
call257.50.153.302.350.75016.000.000.349-1.2340.069
call2600.401.600.800.59925.004.000.261-0.9720.061
call262.50.150.901.640.5587.000.000.186-0.7570.050
call2650.100.750.490.60441.000.000.164-0.7830.046
call267.50.050.750.730.67916.000.000.143-0.7770.042
call2700.052.451.000.75127.000.000.126-0.7670.039
call272.50.002.350.000.7840.000.000.127-0.8140.040
call2750.002.300.510.8891270.000.101-0.7440.033
call277.50.002.250.360.9552.000.000.092-0.7350.031
call2800.000.750.301.0208.000.000.088-0.7540.030
call282.50.002.200.001.0830.000.000.083-0.7720.029
call2850.002.150.001.1580.000.000.079-0.7790.028
call2900.002.150.001.2590.000.000.074-0.8160.026
call2950.000.300.721.1401.000.000.036-0.4130.015
call3000.001.950.001.2500.000.000.034-0.4330.014
call3050.001.950.001.3460.000.000.032-0.4430.013
call3100.002.150.001.4110.000.000.030-0.4390.013
call3150.002.150.001.5150.000.000.028-0.4560.012
call3200.002.150.001.6140.000.000.027-0.4660.012
call3250.002.150.001.7050.000.000.026-0.4700.011
put1150.002.150.115.4351.000.00-0.017-1.0580.008
put1200.002.150.005.1700.000.00-0.018-1.0510.009
put1250.002.150.004.9150.000.00-0.019-1.0430.009
put1300.002.150.004.6700.000.00-0.020-1.0350.009
put1350.002.150.004.4340.000.00-0.021-1.0260.010
put1400.002.150.004.2060.000.00-0.022-1.0170.010
put1450.002.150.003.9850.000.00-0.024-1.0080.011
put1500.002.150.003.7720.000.00-0.025-0.9970.011
put1550.002.150.003.5650.000.00-0.026-0.9870.012
put1600.002.150.003.3520.000.00-0.028-0.9770.012
put1650.002.150.003.1370.000.00-0.030-0.9640.013
put1700.002.150.002.9450.000.00-0.032-0.9510.014
put1750.002.150.002.7580.000.00-0.034-0.9370.014
put1800.002.150.002.5950.000.00-0.036-0.9390.015
put1850.002.150.002.4240.000.00-0.038-0.9250.016
put1900.002.151.062.2801.000.00-0.041-0.9190.016
put1950.002.150.402.10783.000.00-0.044-0.9020.017
put2000.000.751.081.9341.000.00-0.047-0.8810.018
put2050.000.951.161.7642.000.00-0.051-0.8590.020
put2100.000.951.781.5965.000.00-0.056-0.8340.021
put212.50.001.550.001.5120.000.00-0.059-0.8190.022
put2150.001.150.001.4300.000.00-0.062-0.8070.023
put217.50.000.750.171.3471.000.00-0.065-0.7920.024
put2200.000.950.051.2644360.00-0.069-0.7760.025
put222.50.001.550.001.1630.000.00-0.074-0.7480.026
put2250.000.950.341.09944.000.00-0.078-0.7400.027
put227.50.000.750.431.0162.000.00-0.084-0.7270.029
put2300.002.450.100.9492900.00-0.094-0.7410.032
put232.50.002.550.000.8700.000.00-0.095-0.6590.032
put2350.100.800.950.77915.000.00-0.115-0.7080.036
put237.50.051.752.300.7893.000.00-0.158-0.8980.045
put2400.052.650.300.69428.000.00-0.175-0.8440.048
put242.50.102.801.000.59623.000.00-0.200-0.8010.053
put2450.401.201.330.49524.000.00-0.248-0.8180.059
put247.50.403.701.810.7574.000.00-0.360-1.2120.070
put2501.354.702.760.74929.000.00-0.430-1.1820.074
put252.52.655.003.300.6242.000.00-0.514-1.0780.075
put2554.206.908.900.6882.000.00-0.587-1.2010.073
put257.55.808.300.000.6590.000.00-0.651-1.2050.069
put2607.9010.5011.200.7242.000.00-0.739-0.9430.061
put262.59.4012.405.400.7242.000.00-0.814-0.7270.050
put26511.5015.500.000.9220.000.00-0.836-0.7530.046
put267.514.0017.900.000.9970.000.00-0.857-0.7470.042
put27016.3020.500.001.0650.000.00-0.874-0.7370.039
put272.519.0022.700.001.1300.000.00-0.887-0.7240.036
put27521.6025.200.001.2100.000.00-0.899-0.7130.033
put277.523.9027.800.001.3070.000.00-0.908-0.7040.031
put28027.0030.000.001.3860.000.00-0.912-0.7230.030
put282.528.8032.9029.201.4612.000.00-0.917-0.7400.029
put28531.4035.000.001.5330.000.00-0.920-0.7560.028
put29036.3040.200.001.6500.000.00-0.926-0.7860.026
put29541.6045.200.001.7850.000.00-0.964-0.3900.015
put30046.6050.200.001.9140.000.00-0.966-0.4000.014
put30551.7055.2047.202.0380.000.00-0.968-0.4090.013
put31056.6060.2052.302.1590.000.00-0.970-0.4170.013
put31561.7065.200.002.2760.000.00-0.972-0.4250.012
put32066.6070.200.002.3890.000.00-0.973-0.4320.012
put32571.5075.200.002.4990.000.00-0.974-0.4380.011

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13GSEC
2026-11-024Statement of changes in beneficial ownership of securities2026-10-30SEC
2026-10-2810-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-288-KCurrent report2026-10-28SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-08-123Initial statement of beneficial ownership of securities2026-08-03SEC
2026-08-06SCHEDULE 13G/ASEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-04144Filing for proposed sale of securities under Rule 144.SEC
2026-08-03144Filing for proposed sale of securities under Rule 144.SEC
2026-07-2910-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-298-KCurrent report2026-07-29SEC
2026-07-018-KCurrent report2026-07-01SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-108-KCurrent report2026-06-09SEC
2026-06-108-K/A2026-05-14SEC
2026-06-05SCHEDULE 13G/ASEC
2026-05-148-KCurrent report2026-05-14SEC
2026-05-14SC TO-T/ASEC
2026-05-14SCHEDULE 13D/ASEC
2026-05-12SC TO-T/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-0800239.75K2
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-025851665.66K2
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
FMR LLC11.36%
BlackRock, Inc.10.83%
PRIMECAP MANAGEMENT CO/CA/10.26%
VANGUARD CAPITAL MANAGEMENT LLC6.54%
STATE STREET CORP4.97%
VANGUARD PORTFOLIO MANAGEMENT LLC4.47%
GEODE CAPITAL MANAGEMENT, LLC3.05%
WELLINGTON MANAGEMENT GROUP LLP2.11%
NORGES BANK1.75%
MORGAN STANLEY1.63%

Funds

Fund% owned
Core Fixed Income Fund43.99%
Lord Abbett Ultra Short Bond Fund30.13%
VANGUARD SHORT-TERM CORPORATE BOND INDEX FUND16.28%
VANGUARD INTERMEDIATE-TERM CORPORATE BOND INDEX FUND13.89%
DFA Investment Grade Portfolio11.56%
Bramshill Income Performance Fund8.99%
iShares iBoxx $ Investment Grade Corporate Bond ETF8.81%
VANGUARD LONG-TERM CORPORATE BOND INDEX FUND7.83%
Touchstone Strategic Trust-Touchstone Flexible Income Fund7.81%
Invesco BulletShares 2030 Corporate Bond ETF7.39%

OakChart. BIIB. Cached 15 minutes.